RT Journal Article
SR Electronic
T1 Hematocrit and Progressive Stroke in Single Small Subcortical Infarction: Insights from the China Stroke Registry III
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.26.24318033
DO 10.1101/2024.11.26.24318033
A1 Lu, Jiancong
A1 Hankey, Graeme J.
A1 Zhang, Xiaoli
A1 Meng, Xia
A1 Zeng, Weiqi
A1 Jiang, Jun
A1 Wang, Anxin
A1 Tan, Zefeng
YR 2024
UL http://medrxiv.org/content/early/2024/11/29/2024.11.26.24318033.abstract
AB Background and Purpose Single Small Subcortical Infarction (SSSI) is a subtype of ischemic stroke with unique pathophysiology, often leading to poor outcomes. This study investigates the association between admission hematocrit (HCT) levels and the risk of progressive stroke in SSSI patients.Methods We conducted a retrospective cohort study using data from the China National Stroke Registry III, including 2,457 SSSI patients. Progressive stroke was defined as an increase in the NIHSS score by ≥2 points during hospitalization. Logistic regression models assessed the association between HCT levels and progressive stroke risk.Results Among 2,457 SSSI patients, 135 (5.50%) experienced progressive stroke. Higher HCT levels were independently associated with a lower risk of progressive stroke (adjusted OR 0.983, 95% CI 0.973-0.994, P = 0.002), with a potential dose-response relationship. The protective effect was more pronounced in patients with severe sensory deficits (P for interaction = 0.013) and younger age (<65 years) (P for interaction = 0.037). Lower HCT levels were also independently associated with increased mortality risk within 3 months after stroke (adjusted OR 0.937, 95% CI 0.892-0.984, P < 0.001).Conclusions Higher admission HCT levels are associated with a lower risk of progressive stroke in SSSI patients, particularly those with severe sensory deficits and younger age. Lower HCT levels may also increase early mortality risk. These findings highlight the importance of monitoring and optimizing HCT levels in SSSI management. Further research should explore the underlying mechanisms and therapeutic implications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnonAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval number: KY2015-001-01I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data are available upon reasonable request.